

TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS)



Dell T, Menne M, Praktijnjo M. How Controlled is the Expansion of VIATORR CX? *Cardiovascular Interventional Radiology* 2023;46(5):658-663.

OPEN ACCESS (OP993)

Gore products referenced within, if any, are used within their approved/cleared indications (FDA or CE Mark). Gore does not have knowledge of the indications and approval/clearance status of non-Gore products or surgical techniques. Gore makes no representations as to the diagnoses, surgical techniques, medical conditions or other factors that may be described in this article. The reader is advised to contact respective manufacturer(s) for current and accurate information.

Larrue H, D'Amico G, Olivas P, *et al.* TIPS prevents further decompensation and improves survival in patients with cirrhosis and portal hypertension in an individual patient data meta-analysis. *Journal of Hepatology* 2023;79(3):692-703.

No open access available, copy OP970 available upon request to the Gore representative.

Gore products referenced within, if any, are used within their approved/cleared indications (FDA or CE Mark). Gore does not have knowledge of the indications and approval/clearance status of non-Gore products or surgical techniques. Gore makes no representations as to the diagnoses, surgical techniques, medical conditions or other factors that may be described in this article. The reader is advised to contact respective manufacturer(s) for current and accurate information.



Bañares R, Albillos A, Nakum M, *et al.* An Economic Analysis of Transjugular Intrahepatic Portosystemic Covered Stent Shunt for Variceal Bleeding and Refractory Ascites in a Spanish Setting. *Advances in Therapy* 2023;40(7):3006-3020.

OPEN ACCESS (OP965)

Gore products referenced within, if any, are used within their approved/cleared indications (FDA or CE Mark). Gore does not have knowledge of the indications and approval/clearance status of non-Gore products or surgical techniques. Gore makes no representations as to the diagnoses, surgical techniques, medical conditions or other factors that may be described in this article. The reader is advised to contact respective manufacturer(s) for current and accurate information.



Praktijnjo M, Abu-Omar J, Chang J, *et al.* Controlled underdilation using novel Viatorr controlled expansion stents improves survival after trans-jugular intrahepatic portosystemic shunt implantation. *JHEP Reports* 2021;3(3):100264.

OPEN ACCESS (OP981)

Gore products referenced within, if any, are used within their approved/cleared indications (FDA or CE Mark). Gore does not have knowledge of the indications and approval/clearance status of non-Gore products or surgical techniques. Gore makes no representations as to the diagnoses, surgical techniques, medical conditions or other factors that may be described in this article. The reader is advised to contact respective manufacturer(s) for current and accurate information.



Consult Instructions
for Use
eifu.goremedical.com

Refer to *Instructions for Use* at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. Rx only


Products listed may not be available in all markets.

GORE, *Together, improving life*, VIATORR and designs are trademarks of W. L. Gore & Associates.
© 2024 W. L. Gore & Associates GmbH 24PL2052-EN02 JULY 2024

W. L. Gore & Associates, Inc.
goremedical.com

Asia Pacific +65 6733 2882 Australia/New Zealand 1800 680 424 Europe 00800 6334 4673
United States Flagstaff, AZ 86004 800 437 8181 928 779 2771





SELECTED TIPS LITERATURE

GORE® VIATORR®
Device

Together, improving life



VARICEAL BLEEDING

Nicoară-Farcău O, Han G, Rudler M, *et al.* Preemptive TIPS Individual Data Metanalysis, International Variceal Bleeding Study and Baveno Cooperation Study Groups. Effects of early placement of transjugular shunts in patients with high-risk acute variceal bleeding: a meta-analysis of individual patient data. *Gastroenterology* 2021;160(1):193-205.e10.

No open access available, copy EU124 available upon request to the Gore representative.

Gore products referenced within, if any, are used within their approved/cleared indications (FDA or CE Mark). Gore does not have knowledge of the indications and approval/clearance status of non-Gore products or surgical techniques. Gore makes no representations as to the diagnoses, surgical techniques, medical conditions or other factors that may be described in this article. The reader is advised to contact respective manufacturer(s) for current and accurate information.



Helzberg J, Henson J, Muir A. Recent updates in pre-emptive transjugular intrahepatic portosystemic shunt for acute variceal bleeding. *Clinical Liver Disease* 2022;20(3):97-101.

OPEN ACCESS (OP960)

Gore products referenced within, if any, are used within their approved/cleared indications (FDA or CE Mark). Gore does not have knowledge of the indications and approval/clearance status of non-Gore products or surgical techniques. Gore makes no representations as to the diagnoses, surgical techniques, medical conditions or other factors that may be described in this article. The reader is advised to contact respective manufacturer(s) for current and accurate information.



Pfisterer N, Unger L, Reiberger T. Clinical algorithms for the prevention of variceal bleeding and rebleeding in patients with liver cirrhosis. *World Journal of Hepatology* 2021;13(7):731-746.

OPEN ACCESS (OP964)

Gore products referenced within, if any, are used within their approved/cleared indications (FDA or CE Mark). Gore does not have knowledge of the indications and approval/clearance status of non-Gore products or surgical techniques. Gore makes no representations as to the diagnoses, surgical techniques, medical conditions or other factors that may be described in this article. The reader is advised to contact respective manufacturer(s) for current and accurate information.



Escorsell A, García-Pagán J, Alvarado-Tapia E, *et al.* Pre-emptive TIPS for the treatment of bleeding from gastric fundal varices: Results of a randomised controlled trial. *HEP Reports* 2023;5(6):100717.

OPEN ACCESS (OP961)

Gore products referenced within, if any, are used within their approved/cleared indications (FDA or CE Mark). Gore does not have knowledge of the indications and approval/clearance status of non-Gore products or surgical techniques. Gore makes no representations as to the diagnoses, surgical techniques, medical conditions or other factors that may be described in this article. The reader is advised to contact respective manufacturer(s) for current and accurate information.

ASCITES



Bureau C, Thabut D, Oberti D, *et al.* Transjugular intrahepatic portosystemic shunts with covered stents increase transplant-free survival of patients with cirrhosis and recurrent ascites. *Gastroenterology* 2017;152(1):157-163.

OPEN ACCESS (RP1735)

Gore products referenced within, if any, are used within their approved/cleared indications (FDA or CE Mark). Gore does not have knowledge of the indications and approval/clearance status of non-Gore products or surgical techniques. Gore makes no representations as to the diagnoses, surgical techniques, medical conditions or other factors that may be described in this article. The reader is advised to contact respective manufacturer(s) for current and accurate information.



Piecha F, Radunski UK, Ozga AK, *et al.* Ascites control by TIPS is more successful in patients with a lower paracentesis frequency and is associated with improved survival. *JHEP Reports* 2019;1(2):90-98.

OPEN ACCESS (EU117)

Gore products referenced within, if any, are used within their approved/cleared indications (FDA or CE Mark). Gore does not have knowledge of the indications and approval/clearance status of non-Gore products or surgical techniques. Gore makes no representations as to the diagnoses, surgical techniques, medical conditions or other factors that may be described in this article. The reader is advised to contact respective manufacturer(s) for current and accurate information.



Will V, Rodrigues S, Berzigotti A. Current treatment options of refractory ascites in liver cirrhosis — A systematic review and meta-analysis. *Digestive and Liver Disease* 2022;54(8):1007-1014.

OPEN ACCESS (OP978)

Gore products referenced within, if any, are used within their approved/cleared indications (FDA or CE Mark). Gore does not have knowledge of the indications and approval/clearance status of non-Gore products or surgical techniques. Gore makes no representations as to the diagnoses, surgical techniques, medical conditions or other factors that may be described in this article. The reader is advised to contact respective manufacturer(s) for current and accurate information.



Wong F. Management of refractory ascites. *Clinical and Molecular Hepatology* 2023;29(1):16-32.

OPEN ACCESS (OP979)

Gore products referenced within, if any, are used within their approved/cleared indications (FDA or CE Mark). Gore does not have knowledge of the indications and approval/clearance status of non-Gore products or surgical techniques. Gore makes no representations as to the diagnoses, surgical techniques, medical conditions or other factors that may be described in this article. The reader is advised to contact respective manufacturer(s) for current and accurate information.



Rudler M, Mallet M, Sultanik P, *et al.* Optimal management of ascites. *Liver International* 2020;40(Supplement 1):128-135. Erratum in: *Liver International* 2020;40(5):1247.

OPEN ACCESS (OP991)

Gore products referenced within, if any, are used within their approved/cleared indications (FDA or CE Mark). Gore does not have knowledge of the indications and approval/clearance status of non-Gore products or surgical techniques. Gore makes no representations as to the diagnoses, surgical techniques, medical conditions or other factors that may be described in this article. The reader is advised to contact respective manufacturer(s) for current and accurate information.